Loading clinical trials...
Loading clinical trials...
A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase
Conditions
Interventions
[177Lu]Lu-DOTA-TATE
Atezolizumab
+3 more
Locations
40
United States
Georgetown University Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Advent Health Cancer Institute
Orlando, Florida, United States
University Cancer and Blood Center LLC
Athens, Georgia, United States
University of Kentucky
Lexington, Kentucky, United States
St. Louis University
St Louis, Missouri, United States
Hackensack Meridian Health
Edison, New Jersey, United States
Start Date
July 13, 2022
Primary Completion Date
March 9, 2029
Completion Date
March 23, 2029
Last Updated
March 17, 2026
NCT07037758
NCT05468489
NCT07547332
NCT06323265
NCT04346914
NCT05055999
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions